Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 24292520)

1.

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, Al-Ali HK.

Bone Marrow Transplant. 2014 Feb;49(2):179-84. doi: 10.1038/bmt.2013.173. Epub 2013 Dec 2.

PMID:
24292520
2.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S.

Blood. 2015 Jun 29. pii: blood-2015-03-633404. [Epub ahead of print]

PMID:
26124496
3.

Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis.

Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S.

Haematologica. 2015 Jun 18. pii: haematol.2015.126821. [Epub ahead of print]

4.

Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.

Iurlo A, Cattaneo D, Boiocchi L, Orofino N, Fermo E, Cortelezzi A, Gianelli U.

Ann Hematol. 2015 Jun 18. [Epub ahead of print] No abstract available.

PMID:
26082334
5.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S.

Haematologica. 2015 Jun 11. pii: haematol.2014.119545. [Epub ahead of print]

6.

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.

Barosi G, Rosti V, Gale RP.

Onco Targets Ther. 2015 May 18;8:1091-102. doi: 10.2147/OTT.S31916. eCollection 2015. Review.

7.

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with Ruxolitinib.

Fabiano A, Calzavara Pinton P, Monari P, Moggio E, Pellacani G, Manganoni AM, Gualdi G.

Br J Dermatol. 2015 May 22. doi: 10.1111/bjd.13922. [Epub ahead of print]

PMID:
25997466
8.

Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.

Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F.

Ann Hematol. 2015 May 16. [Epub ahead of print] No abstract available.

PMID:
25975976
9.

Ruxolitinib is Manageable in Myelofibrosis Patients with a Platelet Count ≤ 50 × 109/L. - A Report on 12 Danish Patients.

Bjørn ME, Holmström MO, Hasselbalch HC.

Leuk Lymphoma. 2015 May 2:1-10. [Epub ahead of print]

PMID:
25936872
10.

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Breccia M, Molica M, Colafigli G, Alimena G.

Expert Rev Hematol. 2015 Apr 27:1-3. [Epub ahead of print]

PMID:
25915176
11.

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib.

Harrison C.

Haematologica. 2015 Apr;100(4):409-11. doi: 10.3324/haematol.2015.124099. No abstract available.

12.

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.

Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C.

Br J Haematol. 2015 Jul;170(1):29-39. doi: 10.1111/bjh.13379. Epub 2015 Mar 30.

PMID:
25824940
13.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D.

Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.

PMID:
25824483
14.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F.

Blood. 2015 May 21;125(21):3347-50. doi: 10.1182/blood-2014-10-608315. Epub 2015 Mar 17.

PMID:
25784679
15.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA.

Blood. 2015 Apr 23;125(17):2649-55. doi: 10.1182/blood-2013-02-484832. Epub 2015 Mar 11.

PMID:
25762180
16.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Arana Yi C, Tam CS, Verstovsek S.

Future Oncol. 2015 Mar;11(5):719-33. doi: 10.2217/fon.14.272.

PMID:
25757677
17.

Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.

Chatterjee B, Rqieh U, Greaves P, Piras D, Firth J, Saja K.

Br J Haematol. 2015 May;169(3):307. doi: 10.1111/bjh.13334. Epub 2015 Feb 23. No abstract available.

PMID:
25707420
18.

Pulmonary arterial hypertension exacerbated by ruxolitinib.

Low AT, Howard L, Harrison C, Tulloh RM.

Haematologica. 2015 Jun;100(6):e244-5. doi: 10.3324/haematol.2014.120816. Epub 2015 Feb 14. No abstract available.

19.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):214-221.e1. doi: 10.1016/j.clml.2014.12.008. Epub 2014 Dec 27.

20.

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R.

Bone Marrow Transplant. 2015 May;50(5):628-36. doi: 10.1038/bmt.2014.323. Epub 2015 Feb 9. Review.

PMID:
25665047
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk